Skip to main content
letter
. 2022 Jul 13;10:47. doi: 10.1186/s40364-022-00396-y

Fig. 2.

Fig. 2

ZG16 improves the effect of chemotherapy and promotes T-cell mediated immunity a Growth curve of CT26 and CT26-ZG16 xenografts (n = 6). Data are shown as mean ± s.d.. **P < 0.01 by two-way ANOVA with Tukey’s multiple comparisons test. b the Tumor volume of CT26 and CT26-ZG16 xenografts. c H& E and IHC analysis (ZG16, CD3, PD1, PD-L1) of CT26 and CT26-ZG16 xenografts. Scale bar = 400 μm. d-e Tumor volume and growth curve of MC38 and MC38-ZG16 xenografts treated with PBS or 5-FU(n = 3). Data are shown as mean ± s.d..*P < 0.05, ***P < 0.001 by two-way ANOVA with Tukey's multiple comparisons tests. f-g Tumor volume and growth curve of MC38 xenografts treated with 5-FU, ZG16 protein or their combination (n = 3). Data are shown as mean ± s.d.***P < 0.001 by two-way ANOVA with Tukey’s multiple comparisons test